% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Holleczek:143862,
      author       = {B. Holleczek$^*$ and C. Stegmaier and J. C. Radosa and
                      E.-F. Solomayer and H. Brenner$^*$},
      title        = {{R}isk of loco-regional recurrence and distant metastases
                      of patients with invasive breast cancer up to ten years
                      after diagnosis - results from a registry-based study from
                      {G}ermany.},
      journal      = {BMC cancer},
      volume       = {19},
      number       = {1},
      issn         = {1471-2407},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {DKFZ-2019-01424},
      pages        = {520},
      year         = {2019},
      abstract     = {Population-based estimates of the long-term risk of
                      loco-regional recurrence and distant metastases of breast
                      cancer (BRC) patients are scant, as most published studies
                      used hospital-based cohorts or participants of clinical
                      trials. This work aims to extend available knowledge by
                      providing population-based long-term estimates of the
                      cumulative risk of BRC recurrence up to 10 years after
                      diagnosis.Data from the population-based Saarland Cancer
                      Registry were used and included 9359 female patients with
                      primary invasive BRC diagnosed between 1999 and 2009.
                      Estimates of the cumulative incidence (CI) of BRC recurrence
                      were derived for patients who had received local surgery
                      with free resection margins by type of recurrence and
                      stratified by age, tumor characteristics and major treatment
                      options, taking into account mortality from any cause as a
                      competing risk.The 10-year CI of BRC recurrence was $16\%.$
                      For loco-regional recurrence and distant metastases alone it
                      was 8 and $11\%,$ respectively. The estimates showed
                      substantial variation and were particularly increased if
                      tumors were advanced $(T1/2N+ 23\%,$ T3/4N0 $24\%,$
                      $T3/4N+ 34\%),$ of high grade $(23\%),$ or of 'HER2/neu
                      positive' $(28\%)$ or 'triple negative' subtype $(23\%),$
                      respectively.The derived estimates reflect the risk of 'real
                      world' patients and may therefore extend available
                      knowledge. These data are thus of great relevance for
                      clinicians, their patients and researchers. The study
                      likewise demonstrated the usefulness of cancer registries
                      for a population-based monitoring of the effectiveness of
                      cancer care in terms of disease recurrence as a major
                      treatment related outcome measure.},
      cin          = {C070 / C120 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331 / I:(DE-He78)C120-20160331 /
                      I:(DE-He78)L101-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31146706},
      doi          = {10.1186/s12885-019-5710-5},
      url          = {https://inrepo02.dkfz.de/record/143862},
}